Search Legislation

Regulation (EC) No 1223/2009 of the European Parliament and of the CouncilShow full title

Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast) (Text with EEA relevance)

 Help about what version

What Version

 Help about advanced features

Advanced Features

 Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

This item of legislation originated from the EU

Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).

Status:

Point in time view as at 03/12/2020.

Changes to legislation:

There are currently no known outstanding effects for the Regulation (EC) No 1223/2009 of the European Parliament and of the Council, ANNEX VI. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

ANNEX VIU.K.LIST OF UV FILTERS ALLOWED IN COSMETIC PRODUCTS

a

Not required if concentration is 0,5 % or less and when it is used only for product protection purposes.

b

[F1For use as a colorant, see Annex IV, No 143.]

c

[F2In case of combined use of zinc oxide and zinc oxide (nano), the sum shall not exceed the limit given in column g.]

d

[F3In case of combined use of Titanium Dioxide and Titanium Dioxide (nano), the sum shall not exceed the limit given in column g.]

e

[F4In case of combined use of Methylene Bis-Benzotriazolyl Tetramethylbutylphenol and Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (nano), the sum shall not exceed the limit given in column g.]

Reference numberSubstance identificationConditionsWording of conditions of use and warnings
Chemical name/INN/XANName of Common Ingredients GlossaryCAS numberEC numberProduct type, body partsMaximum concentration in ready for use preparationOther
abcdefghi
[F51 ]
2 N,N,N-Trimethyl-4-(2-oxoborn-3-ylidenemethyl) anilinium methyl sulfateCamphor Benzalkonium Methosulfate52793-97-2258-190-86 %
3Benzoic acid, 2-hydroxy-, 3,3,5-trimethylcyclohexyl ester/HomosalateHomosalate118-56-9204-260-810 %
[F64 2-Hydroxy-4-methoxybenzophenone/Oxybenzone Benzophenone-3 131-57-7 205-031-5 6 % Not more than 0,5 % to protect product formulation Contains Benzophenone-3] a
5Moved or deleted
62-Phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanolamine salts/EnsulizolePhenylbenzimidazole Sulfonic Acid27503-81-7248-502-08 %(as acid)
73,3'-(1,4-Phenylenedimethylene) bis(7, 7-dimethyl-2-oxobicyclo-[2.2.1]hept-1-yl-methanesulfonic acid) and its salts/EcamsuleTerephthalylidene Dicamphor Sulfonic Acid92761-26-7, 90457-82-2410-960-610 %(as acid)
81-(4-tert-Butylphenyl)-3-(4-methoxyphenyl)propane-1,3-dione/AvobenzoneButyl Methoxydibenzoylmethane70356-09-1274-581-65 %
9alpha-(2-Oxoborn-3-ylidene)-toluene-4-sulphonic acid and its saltsBenzylidene Camphor Sulfonic Acid56039-58-86 % (as acid)
102-Cyano-3,3-diphenyl acrylic acid, 2-ethylhexyl ester/OctocrileneOctocrylene6197-30-4228-250-810 % (as acid)
11Polymer of N-{(2 and 4)-[(2-oxoborn-3-ylidene)methyl]benzyl} acrylamidePolyacrylamidomethyl Benzylidene Camphor113783-61-26 %
122-Ethylhexyl 4-methoxycinnamate/OctinoxateEthylhexyl Methoxycinnamate5466-77-3226-775-710 %
13Ethoxylated ethyl-4-aminobenzoatePEG-25 PABA116242-27-410 %
14Isopentyl-4-methoxycinnamate/AmiloxateIsoamyl p-Methoxycinnamate71617-10-2275-702-510 %
152,4,6-Trianilino-(p-carbo-2'-ethylhexyl-1'-oxy)-1,3,5-triazineEthylhexyl Triazone88122-99-0402-070-15 %
16Phenol,2-(2H-benzotriazol-2-yl)-4-methyl-6-(2-methyl-3-(1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy)-disiloxanyl)propyl)Drometrizole Trisiloxane155633-54-815 %
17Benzoic acid, 4,4-((6-((4-(((1,1-dimethylethyl)amino)carbonyl)phenyl)amino)-1,3,5-triazine-2,4-diyl)diimino)bis-, bis (2-ethylhexyl) ester/Iscotrizinol (USAN)Diethylhexyl Butamido Triazone154702-15-510 %
183-(4-Methylbenzylidene)-d1 camphor/Enzacamene4-Methylbenzylidene Camphor38102-62-4/36861-47-9- / 253-242-64 %
[ F7 ]
202-Ethylhexyl salicylate/OctisalateEthylhexyl Salicylate118-60-5204-263-45 %
212-Ethylhexyl 4-(dimethylamino)benzoate/Padimate O (USAN:BAN)Ethylhexyl Dimethyl PABA21245-02-3244-289-38 %
222-Hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt/SulisobenzoneBenzophenone-4, Benzophenone-54065-45-6/6628-37-1223-772-2 / -5 % (as acid)
[F823 2,2′-Methylene- bis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol)/Bisoctrizole Methylene Bis-Benzotriazolyl Tetramethylbutylphenol 103597-45-1 403-800-1 10 % e ]
[F423a 2,2′-Methylene- bis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol)/Bisoctrizole Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (nano) 103597-45-1 403-800-1 10 % e

Not to be used in applications that may lead to exposure of the end user's lungs by inhalation.

Only nanomaterials having the following characteristics are allowed:

  • Purity ≥ 98,5 %, with 2,2′-methylene-bis-(6(2H-benzotriazol-2-yl)-4-(isooctyl)phenol) isomer fraction not exceeding 1,5 %;

  • Solubility < 5 ng/L in water at 25 °C;

  • Partition coefficient (Log Pow): 12,7 at 25 °C;

  • Uncoated;

  • Median particle size D50 (50 % of the number below this diameter): ≥ 120 nm of mass distribution and/or ≥ 60 nm of number size distribution.

]
24Sodium salt of 2,2'-bis(1,4-phenylene)-1H-benzimidazole-4,6-disulfonic acid) / Bisdisulizole disodium (USAN)Disodium Phenyl Dibenzimidazole Tetrasulfonate180898-37-7429-750-010 % (as acid)
252,2'-(6-(4-Methoxyphenyl)-1,3,5-triazine-2,4-diyl)bis(5-((2-ethylhexyl)oxy)phenol) / BemotrizinolBis-Ethylhexyloxyphenol Methoxyphenyl Triazine187393-00-610 %
26DimethicodiethylbenzalmalonatePolysilicone-15207574-74-1426-000-410 %
[F127 Titanium dioxide b Titanium Dioxide

13463-67-7/

1317-70-0/

1317-80-2

236-675-5/

215-280-1/

215-282-2

25 % d ]
[F927a Titanium dioxide b Titanium Dioxide (nano) 13463-67-7/1317-70-0/1317-80-2 236-675-5/215-280-1/215-282-2 25 % d

Not to be used in applications that may lead to exposure of the end-user’s lungs by inhalation.

Only nanomaterials having the following characteristics are allowed:

  • purity ≥ 99 %,

  • rutile form, or rutile with up to 5 % anatase, with crystalline structure and physical appearance as clusters of spherical, needle, or lanceolate shapes,

  • median particle size based on number size distribution ≥ 30 nm,

  • aspect ratio from 1 to 4,5, and volume specific surface area ≤ 460 m 2 /cm 3 ,

  • coated with Silica, Hydrated Silica, Alumina, Aluminium Hydroxide, Aluminium Stearate, Stearic Acid, Trimethoxycaprylylsilane, Glycerin, Dimethicone, Hydrogen Dimethicone, Simethicone,

or coated with one of the following combinations:

  • Silica at a maximum concentration of 16 % and Cetyl Phosphate at a maximum concentration of 6 %,

  • Alumina at a maximum concentration of 7 % and Manganese Dioxide at a maximum concentration of 0,7 % (not to be used in lip products),

  • Alumina at a maximum concentration of 3 % and Triethoxycaprylylsilane at a maximum concentration of 9 %,

  • photocatalytic activity ≤ 10 % compared to corresponding non-coated or non-doped reference,

  • nanoparticles are photostable in the final formulation.

For face products containing Titanium Dioxide (nano) coated with the combination Alumina and Manganese Dioxide:

Not to be used on the lips.]

[F528 Benzoic acid, 2-[-4-(diethylamino)-2-hydroxybenzoyl]-. Hexylester Diethylamino Hydroxy benzoyl Hexyl Benzoate 302776-68-7 443-860-6 10  % ]
[F10 [X129 1,3,5-Triazine, 2,4,6-tris[1,1'-biphenyl]-4-yl-, including as nanomaterial

Tris-biphenyl triazine

Tris-biphenyl triazine (nano)

31274-51-8 10 %

Not to be used in sprays.

Only nanomaterials having the following characteristics are allowed:

  • median primary particle size > 80 nm;

  • Purity ≥ 98 %;

  • Uncoated

] ]
[F230 Zinc oxide Zinc Oxide 1314-13-2 215-222-5 25 % c Not to be used in applications that may lead to exposure of the end-user's lungs by inhalation.
30a Zinc oxide Zinc Oxide (nano) 1314-13-2 215-222-5 25 % c

Not to be used in applications that may lead to exposure of the end-user's lungs by inhalation.

Only nanomaterials having the following characteristics are allowed:

  • purity ≥ 96 %, with wurtzite crystalline structure and physical appearance as clusters that are rod-like, star-like and/or isometric shapes, with impurities consisting only of carbon dioxide and water, whilst any other impurities are less than 1 % in total,

  • median diameter of the particle number size distribution D50 (50 % of the number below this diameter) > 30 nm and D1 (1 % below this size) > 20 nm,

  • water solubility < 50 mg/L

  • uncoated, or coated with triethoxycaprylylsilane, dimethicone, dimethoxydiphenylsilanetriethoxycaprylylsilane cross-polymer, or octyl triethoxy silane.

]
[F1131 3,3′-(1,4-Phenylene)bis(5,6-diphenyl-1,2,4-triazine) Phenylene Bis-Diphenyltriazine 55514-22-2 700-823-1 5 % Not to be used in applications that may lead to exposure of the end user's lungs by inhalation. ]
[F1232 2-ethoxyethyl (2Z)-2-cyano-2-[3-(3-methoxypropylamino) cyclohex-2-en-1-ylidene]acetate Methoxypropylamino Cyclohexenylidene Ethoxyethylcyanoacetate 1419401-88-9 700-860-3 3 %
  • Not to be used in applications that may lead to exposure of the end-user’s lungs by inhalation

  • Do not use with nitrosating agents – Maximum nitrosamine content: 50 μg/kg

  • Keep in nitrite-free containers

]

Editorial Information

Textual Amendments

Back to top

Options/Help

Print Options

You have chosen to open the Whole Regulation

The Whole Regulation you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.

Would you like to continue?

You have chosen to open Schedules only

The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.

Would you like to continue?

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the EU Official Journal
  • lists of changes made by and/or affecting this legislation item
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.

The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.

For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources